Avila, acquired by Celgene, was a clinical-stage biotechnology company focused on the design and development of targeted covalent drugs to achieve best-in class outcomes.

The company’s product pipeline was built using its proprietary Avilomics platform with a focus on cancer, viral infection and autoimmune disease. Avila’s most advanced product candidate, AVL-292, a potential treatment for cancer and autoimmune diseases, was in Phase I clinical testing.

Contact Info

100 Beaver Street, Waltham, MA, 02453-8425
Tel: 781-891-0086

Polaris Lead

Amir Nashat